Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Fate Therapeutics
National Cancer Institute (NCI)
University of California, San Francisco
Northwestern University
National Institutes of Health Clinical Center (CC)